T cell ACTs can be directed against surface antigens expressed by tumor cells using chimeric antigen receptors (CARs), intracellular antigens presented by the major histocompatibility complex (MHC) using genetically engineered T cell receptors (TCRs), or peptide-centric (PC) CARs [35,36,37]. Here, HLA-C is linked to neoplasm.